Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JB Chemicals Acquires Several Sanzyme Brands

The $83m Transaction Is Expected To Close Within The Next Two Weeks

Executive Summary

JB Chemicals has purchased a number of leading brands from Sanzyme, which it plans to scale up and institutionalize within India. The transaction, worth over $80m, is expected to close within the next two weeks.

You may also be interested in...



Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort

Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.

Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation

Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.

Who’s Hired? Another Viatris Executive Joins Neuraxpharm

Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel